Replies to post #1122 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

I am still waiting for a drug that helps improve survival of rGBM patients. Even if VB-111 improves survival by only 30 days, it is far better than Avastin when you compare the side effects.

rGBM patients receive VB-111 with Avastin so when bad things happen they blame it on both drugs; they don't really know. But their side effects are very similar to patients taking Avastin alone. Furthermore, ovarian patients on VB-111 are not reporting these side effects.

What the FDA does or does not do with the VB-111 reporting process is irrelevant to me. People are dying and suffering with rGBM. Perhaps all the FDA is trying to do is determine if VB-111 is effective and get it to market asap.